News Conference News AHA 2024 ARNI Lessens Anthracycline Cardiotoxicity in High-Risk Patients: SARAH Caitlin E. Cox November 18, 2024
News Conference News HFSA 2024 FINEARTS-HF: New Analyses Ask, Who Benefits Most From Finerenone? Michael O'Riordan October 02, 2024
News Conference News HFSA 2022 GDMT With ARNI Linked to Less MR, May Obviate Need for Interventions Michael O'Riordan October 04, 2022
News Conference News ESC Heart Failure 2022 Dapagliflozin Boosts Health Status Across LVEF Range Shelley Wood May 23, 2022
News Conference News ESC 2021 Fixed-Dose Combo Therapy Slashes CVD Risk in Primary Prevention Michael O'Riordan August 31, 2021
News Conference News ACC 2021 Sotagliflozin Beneficial Across a Range of Patients, Including HFpEF Michael O'Riordan May 25, 2021
News Conference News ACC 2021 Sacubitril/Valsartan Lowers Triglycerides in HFpEF: PARAGON-HF Yael L. Maxwell May 16, 2021
News Conference News AHA 2020 Sotagliflozin Scores Wins in SCORED and SOLOIST-WHF Trials Michael O'Riordan November 17, 2020
News Conference News ESC 2019 ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More Shelley Wood August 22, 2019
News Conference News ACC 2017 Many Patients Prescribed PCSK9 Inhibitors Never End Up Getting Them Yael L. Maxwell March 23, 2017